Sandbox Reserved 1741: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 24: | Line 24: | ||
== Relevance == | == Relevance == | ||
The finding of HIV-1 RT was monumental for offering treatment to individuals living with HIV-1. After its discovery, the development of nucleoside reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs), which are responsible for inhibition of different mechanisms of reverse transcription. Once the NNRTs come in contact with the RT, the process is stoped and the proviral DNA remains incomplete (6). | The finding of HIV-1 RT was monumental for offering treatment to individuals living with HIV-1. After its discovery, the development of nucleoside reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs), which are responsible for inhibition of different mechanisms of reverse transcription. Once the NNRTs come in contact with the RT, the process is stoped and the proviral DNA remains incomplete (6). | ||
The first drug approved to treat HIV was a NRTI, or a reverse transcriptase inhibitor called '''Zidovudine''' (AZT), and it was released in 1987 (6). Additionally, the are 13 more approved drugs to treat HIV that inhibit RT, and this is out of 26 approved drugs total (4). So, the discovery of reverse transcriptase was imperative to providing treatment to millions of HIV+ patients. | |||
== Structural highlights == | == Structural highlights == | ||
